Journal
MATERIALS SCIENCE AND ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS
Volume 110, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.msec.2019.110591
Keywords
ONO-1301; Prostacyclin analogue; Dual delivery; Small molecule; Bone regeneration
Categories
Funding
- Kerala State Council for Science, Technology and Environment (Kerala State Young Scientist Award Scheme) [KSCSTE/435/2018]
- India-Japan Cooperative Science Programme
- Council of Scientific and Industrial Research (CSIR), Government of India [09/942(0013) 2K17-EMR-I]
Ask authors/readers for more resources
Treatment aiming to enhance bone tissue regeneration can benefit from multiple growth factor or small molecule delivery. In the present study, the objective was to evaluate the feasibility of using nanocomposite fibrous scaffold to deliver prostacyclin I2 agonist ONO-1301 in combination with BMP2 for treating critical sized bone defect. For this, ONO-1301 at three different concentrations (1.67 mu g, 5 mu g, 15 mu g) and a fixed dose of BMP2 (5 mu g) was loaded on the scaffold via physical adsorption. The results showed fast release of ONO-1301 for two weeks, whereas BMP2 exhibited slow and sustained release for four weeks. The scaffold with dual factors promoted the migration and osteogenic differentiation of mesenchymal stem cells (MSCs) in vitro when compared to the scaffold with BMP2 alone. It also augmented bone tissue regeneration in critical sized rat calvarial defect at 12 weeks; mainly with lower dose of ONO-1301. However, synergistic effect on osteogenic differentiation and bone regeneration were not obtained through the concurrent release of BMP-2 and ONO-1301.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available